首页 | 本学科首页   官方微博 | 高级检索  
     

儿童核心结合因子相关急性髓系白血病临床特征及预后分析
引用本文:刘超,陈晓燕,易美慧,吴文齐,阮敏,竺晓凡. 儿童核心结合因子相关急性髓系白血病临床特征及预后分析[J]. 中国当代儿科杂志, 2020, 22(7): 739-743. DOI: 10.7499/j.issn.1008-8830.2002039
作者姓名:刘超  陈晓燕  易美慧  吴文齐  阮敏  竺晓凡
作者单位:刘超, 陈晓燕, 易美慧, 吴文齐, 阮敏, 竺晓凡
摘    要:目的 分析儿童核心结合因子相关急性髓系白血病(CBF-AML)的临床特征及疗效。方法 回顾性分析2009年8月至2015年11月于中国医学科学院血液病医院确诊的初诊CBF-AML患儿的临床资料,根据融合基因类型,分为CBFB-MYH11组和AML1-ETO组。总结并比较其临床特征及预后。结果 共纳入91例初诊CBF-AML患儿,其中AML1-ETO组74例(81%),CBFB-MYH11组17例(19%)。38例(42%)患儿伴有附加染色体异常,其中性染色体缺失28例(31%)最为常见。第1个疗程诱导治疗完全缓解率为97%(88/91),复发率为29%(26/91),5年EFS率为65%±6%,5年OS率为75%±5%。AML1-ETO、CBFB-MYH11组5年EFS率分别为62%±7%、77%±11%(P > 0.05)。AML1-ETO、CBFB-MYH11组5年OS率分别为72%±6%、88%±9%(P > 0.05)。结论 儿童CBF-AML以AML1-ETO为主,性染色体缺失为最常见的附加染色体异常,预后较好,AML1-ETO与CBFB-MYH11患儿预后相当。

关 键 词:急性髓系白血病  核心结合因子  临床特征  预后  儿童  
收稿时间:2020-02-09
修稿时间:2020-05-18

Clinical features and prognosis of core binding factor acute myeloid leukemia in children
LIU Chao,CHEN Xiao-Yan,YI Mei-Hui,WU Wen-Qi,RUAN Min,ZHU Xiao-Fan. Clinical features and prognosis of core binding factor acute myeloid leukemia in children[J]. Chinese journal of contemporary pediatrics, 2020, 22(7): 739-743. DOI: 10.7499/j.issn.1008-8830.2002039
Authors:LIU Chao  CHEN Xiao-Yan  YI Mei-Hui  WU Wen-Qi  RUAN Min  ZHU Xiao-Fan
Affiliation:LIU Chao, CHEN Xiao-Yan, YI Mei-Hui, WU Wen-Qi, RUAN Min, ZHU Xiao-Fan
Abstract:Objective To study the clinical features and prognosis of core binding factor acute myeloid leukemia (CBF-AML) in children. Methods A retrospective analysis was performed from the chart review data of children who were newly diagnosed with CBF-AML in the Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences, from August 2009 to November 2015. According to the type of fusion gene, the children were divided into CBFB-MYH11 and AML1-ETO groups. Clinical features and prognosis were analyzed and compared between the two groups. Results A total of 91 children with CBF-AML were enrolled in this study, among whom there were 74 (81%) in the AML1-ETO group and 17 (19%) in the CBFB-MYH11 group. Additional chromosomal abnormalities were observed in 38 children (42%), and deletion of sex chromosome was the most common abnormality and was observed in 28 children (31%). After the first course of induction treatment, the complete remission rate was 97% (88/91), the recurrence rate was 29% (26/91), the 5-year event-free survival (EFS) rate was 65%±6%, and the 5-year overall survival (OS) rate was 75%±5%. There were no significant differences between the AML1-ETO and CBFB-MYH11 groups in 5-year EFS rate (62%±7% vs 77%±11%, P > 0.05) or 5-year OS rate (72%±6% vs 88%±9%, P > 0.05). Conclusions AML1-ETO is the main type of fusion gene in children with CBF-AML, and deletion of sex chromosome is the most common type of additional chromosomal abnormalities. Children with CBF-AML often have a good prognosis, and the children with AML1-ETO have a similar prognosis to those with CBFB-MYH11.
Keywords:

Acute myeloid leukemia|Core binding factor|Clinical feature|Prognosis|Child

本文献已被 CNKI 等数据库收录!
点击此处可从《中国当代儿科杂志》浏览原始摘要信息
点击此处可从《中国当代儿科杂志》下载全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号